secwatch.observer — SEC 8-K summary
======================================

Issuer:     PAVmed Inc. (PAVM)
CIK:        0001624326
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001493152-24-045362
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PAVmed reports Q3 GAAP net income $64.3M driven by deconsolidation; Lucid EsoGuard revenue record $1.2M
--------------------------------------------------------------------------------

- Lucid Q3 EsoGuard revenue $1.2M, a record; 2,787 commercial tests; October single-month record >1,400 tests.
- GAAP net income $64.3M ($1.44 diluted EPS) largely due to Lucid deconsolidation; non-GAAP adjusted loss $5.4M ($0.54/share).
- Cash and equivalents $0.8M as of Sept 30, 2024, down from $19.6M at Dec 31, 2023.
- PAVmed deconsolidated Lucid on Sept 10; reached agreement to exchange $25M convertible debt for preferred equity to regain Nasdaq compliance; extension to Jan 31, 2025.
- Veris completed pilot with Ohio State's James Cancer Hospital and awarded $1.8M NIH grant.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1624326/000149315224045362/0001493152-24-045362-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1624326/000149315224045362/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-045362

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer